The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Why asc down but boo up?
How I wish the herd of Reddit can come to help us with our loop
Thank you both Aspers and Leas.
its very kind of you and be safe and happy holding mate.
on which day will the new issued shares hit the market pls?
thanks in advance
We kicked PT away!
Our asset has been here all the time.
Copper value increased actually,
And exploring keep going on.
Fact!
Start to recovering.
NT to buy
And 2.3775 to sell on a bidding of 2.3
Lovely jubbly
A great chance to top up
Sorted the money issue? 2m ready to transfer in?
Hope so...
Happy to hold 4 million shares now.
Doubled at .29
0.32 and 0.2975 respectively
juicy!
topped up twice this morning. 5000 shares in total.
hold and enjoy
The market cap will be around 1-1.5 billion $, check the P/E ratio of nio, Tesla and plug...all over 1000 I remember
We should be priced 4.20-4.40£ ish.
Great news, great achievement, keep up boohoo, well done!
imagine of a RNS like below when our share price passed 100p
The board noticed the sharp share movement of loopup, we are pleased to notify the market that we were approached by a large international institution...and offered £2.20 on a combination of 50% cash and 50% share issue taking over.
Good luck all holders!
we deserve a bright Christmas!
we guess and we strongly hope that the seller is finally gone. some institute also bought in...market can't ignore true value of a money making company for too long
he knows the co would need money, to issue and to place, he musthave known it, thus sold all of his holding before the announcement.
what an inside trade
over two weeks ago.
how can large share holders get away from that and company directors not doing anything accordingly?
Will London Stock exchange or financial ombudsman be in charge of issues like this?
that caused a fall of 500M, £, not fair.
should bounce back!
good luck all holders and new comers!
you think fair value is?
GORDON JOHNSON: I think fair value for Tesla's probably around $60 to $80. We think it's going to head there. We think it happens next year--
AKIKO FUJITA: $60 to $80.
GORDON JOHNSON: --problem. Want to talk-- oh no, go ahead. I'm sorry.
AKIKO FUJITA: Did you say $60 to $80?
GORDON JOHNSON: Correct.
AKIKO FUJITA: Walk me through your thesis.
GORDON JOHNSON: Right. The thesis is simple. Tesla's currently trading at about 200 times earnings, whereas on average, automakers trade around six times earnings. Tesla is seen as a technology company but they don't have the technology that people think they have, with respect to, there's no, there there, with respect to the batteries.
And with respect to S&P inclusion I think this is important. Since the S&P announced they were going to delay the inclusion about a month and a half ago-- they were going to include them about a month and a half ago-- there's been about a billion shares traded. And prior to that, when they reported a profit in 2Q, there was a billion shares traded around that time.
However, based on the S&P zone estimate, there's about 130 million shares that need to be purchased by indexed fund holders. So the point is, on that inclusion you're going to potentially have a lot of shares that had been front run-- that have been front run, on this inclusion that are going to have to be sold. So you could have a significant sell off on Friday or before Friday as some of that money that went into Tesla's stock looking for inclusion comes off.
Now, to your question of what our thesis is. Listen, next year-- right-- Tesla has only been profitable four quarters out of their entire existence as a company since 2016 excluding credit revenues. These are government funded revenues that Tesla gets. They weren't even profitable last quarter. Next quarter, for the most part, we believe those credit revenues significantly fall and in 2022 go away.
The reason is because every-- every automaker is now selling their own EVs. So if Tesla goes back into loss making status, and when you add to that the fact that even the big jump in their Chinese revenues, their market share in China only went from 8% to 12.5% October to November. The prior high this year was 25%. So they're losing market share in China and their EU market share has fallen from about 33% in Q4 to around just above 10% right now.
So in the markets where you have competition they're losing share. So as their growth slows, as their earnings turn back negative next year, we think there's going to be a significant sell off in the shares. Institutional ownership right now, 41% roughly. Nearly an all time low. As that-- as people start to sell those shares and the retail money, which is driving the stock, starts to sell, we think there's going to be a swift down drift in the stock.
You've seen this before. I know it sounds crazy. Look at Tilray, look at SunEdison, look at Suntech look at som
Yahoo Finance Video
Why one analyst says Tesla investors should expect a ‘significant selloff’
Mon, December 14, 2020, 5:12 PM GMT
GLJ Research Founder and CEO Gordon Johnson joins Yahoo Finance Live to discuss the latest with Tesla and what to expect ahead of the company joining the S&P 500.
Video Transcript
ZACK GUZMAN: I want to spotlight the action we're seeing here in Tesla, with shares in the green following an interesting report on plans for the Model S and X at the electric automaker. Tesla planning to idle production for those models through January 11th according to an email for the plans obtained by CNBC. It's an interesting production pause considering those models are not exactly the most popular. They are only about 11% in terms of deliveries in the latest quarter. And a new report out from electric saying, part of the reason could be that the automaker has already met its goals for Model S and X deliveries for the fourth quarter. Interesting there. Could be driving the price action we're seeing here today.
For more on that, I want to bring on our next guest. That would be Gordon Johnson, GLJ Research CEO and founder here with us. Gordon, appreciate you taking the time here to chat. I mean, it's obvious that Tesla has been focusing more on the cheaper Model 3 here, that's the main driver, of course, the main shift kind of ahead of the incredible rally we've seen here this year. But what do you make of that, and how important is it for Tesla and Elon Musk when we talk about the Model S and X?
GORDON JOHNSON: Well I think it's baffling some people, because just a few days ago Elon Musk put out an email-- an internal email that was leaked to the public-- that said they were effectively production constrained. They needed to significantly increase production. And then a few days later we find out they're shutting down production for S and X for 18 days.
Look, I think it's one of two things. One-- one of two things. One being-- A being, rather, demand is a problem. Or B being, rather, they need to retool or refurbish the Model to make it more attractive. Either way it's a demand problem and kind of stands in contrast to what Elon Musk said it's just a few days ago, i.e. that they were production constrained.
AKIKO FUJITA: So which do you think it is?
GORDON JOHNSON: I think it's probably a combination of both. We know those models haven't sold well, so I think that's a problem for them. But I think there's other issues that we can get into, a couple of actions Tesla has taken recently that suggest demand is really a problem.
ZACK GUZMAN: What might those be, though? Because when we we're talking about a stock that's up so much there this year, people have been talking about the idea that demand has been strong considering, you know, the delivery targets being shattered quarter after quarter for Elon Musk and Co. I mean, it seems like things are moving in the right direction, but I know there are other critics out
People with a history of significant allergic reactions should not have the Pfizer/BioNTech Covid jab, regulators say.
It came after two NHS workers had allergic reactions on Tuesday.
The advice applies to those who have had reactions to medicines, food or vaccines, the Medicines and Healthcare products Regulatory Agency said.
The two people had a reaction shortly after having the new jab, had treatment and are both fine now.